Fexapotide triflutate: results of long-term safety and efficacy trials of a novel injectable therapy for symptomatic prostate enlargement

PURPOSE: These studies were undertaken to determine if fexapotide triflutate 2.5 mg transrectal injectable (FT) has significant long-term (LT) safety and efficacy for the treatment of benign prostatic hyperplasia (BPH). METHODS: Two placebo controlled double-blind randomized parallel group trials wi...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :World J Urol
Главные авторы: Shore, Neal, Tutrone, Ronald, Efros, Mitchell, Bidair, Mohamed, Wachs, Barton, Kalota, Susan, Freedman, Sheldon, Bailen, James, Levin, Richard, Richardson, Stephen, Kaminetsky, Jed, Snyder, Jeffrey, Shepard, Barry, Goldberg, Kenneth, Hay, Alan, Gange, Steven, Grunberger, Ivan
Формат: Artigo
Язык:Inglês
Опубликовано: Springer Berlin Heidelberg 2018
Предметы:
Original Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5916987/
https://ncbi.nlm.nih.gov/pubmed/29380128
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00345-018-2185-y
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы